YOLFTbeta
Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX · NASDAQ · Healthcare / Biotechnology

1.11USD-0.01 (-0.89%)

Price History

Full chart

Market Stats

Previous Close1.12
Open1.14
Day Range1.11 – 1.19
52-Week Range1.28 – 9.50
Volume74.49K
Market Cap46.23M
P/E (TTM)0.73
Forward P/E0.00
EPS1.86
Dividend Yield0.00%
Beta1.83
50-Day Avg1.91
200-Day Avg2.42

About

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Gregory Duncan
  • Employees8
  • Headquarters44 Milton Avenue, Alpharetta, GA, United States, 30009, USA
  • Websitehttps://dwtx.com

Leadership

  • Mr. Gregory DuncanChairman & CEO · b. 1965
  • Ms. Angela WalshCFO, Secretary & Treasurer · b. 1967
  • Dr. R. Michael Gendreau M.D., Ph.D.Chief Medical Officer · b. 1956
  • Dr. William L. Pridgen M.D.Founder & Member of Scientific Advisory Board · b. 1961
  • Mr. Ralph D. Grosswald M.P.H.Senior Vice President of Operations · b. 1969
  • Ms. Carol Duffy Ph.D.Chief Scientific Advisor

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--000000
Cost of Revenue------12.18K-
Gross Profit-------12.18K-
Operating Expense------12.22M-
Operating Income-1.96M-2.18M-10.01M-15.64M-12.32M-5.45M-12.23M-27.97M
EBITDA-1.96M-2.18M-10.01M-15.96M-12.25M-5.30M-12.25M-34.03M
Net Income-2.11M-2.47M-10.35M-15.96M-12.25M-5.30M-12.35M-34.26M
R&D854.11K800.62K194.01K10.80M8.07M1.73M3.53M21.87M
Interest Expense152.10K295.13K384.22K---92.19K-

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets65.94K315.90K31.47M15.78M8.37M4.17M94.31M90.17M
Total Liabilities1.33M5.26M1.53M1.28M1.04M358.55K30.03M15.27M
Total Equity-1.26M-4.94M29.94M14.50M7.33M3.81M64.28M74.90M
Cash30.03K309.38K29.80M14.01M7.03M3.32M14.85M6.52M
Total Debt-3.64M----15.59M162.60K
Net Debt-30.03K3.33M-29.80M-14.01M-7.03M-3.32M737.71K-6.36M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.20M-2.09M-3.90M-15.69M-11.47M-4.87M-8.79M-15.62M
Investing Cash Flow------3.76M-
Financing Cash Flow1.15M2.37M33.38M-97.60K4.49M1.16M16.70M7.28M
Capital Expenditure00503050
Free Cash Flow-1.20M-2.09M-3.90M-15.69M-11.47M-4.87M-8.79M-15.62M
Dividends Paid--75.00K0----
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF---1.93%0.00%----

Earnings

Report DateAug 28, 2020Dec 18, 2020Mar 3, 2021May 13, 2021Aug 12, 2021Nov 11, 2021Mar 17, 2022May 12, 2022Aug 11, 2022Nov 14, 2022Mar 14, 2023May 11, 2023Aug 10, 2023Nov 13, 2023Feb 29, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 13, 2025May 8, 2025Aug 13, 2025Nov 6, 2025Mar 18, 2026Mar 31, 2026Aug 13, 2026Nov 5, 2026
EPS Estimate0.000.00--23.25-13.75-17.25-0.54-13.75-12.25-11.50-3.75-0.16-1.25-2.25-0.06-1.00-1.58-1.18-0.06-0.76-1.90-1.58-0.86-0.20-0.13-0.15
EPS Actual-0.08-0.35-1.25-9.25-12.75-12.25-0.54-12.00-11.00-7.00-2.75-0.08-2.00-1.50-0.06-1.75-1.25-2.05-6.29-8.45-1.99-8.20-0.26-0.15-0.34-
Surprise---60.22%7.27%28.99%0.00%12.73%10.20%39.13%26.67%50.00%-60.00%33.33%0.00%-75.00%20.89%-73.73%-10993.47%-1011.84%-4.74%-418.99%69.77%25.00%-161.54%-
Timing---Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap46.23M
Enterprise Value41.68M
Trailing P/E0.73
Forward P/E0.00
Price / Sales0.00
Price / Book0.75
EPS1.86
Book Value2.03
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-29.56M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-47.77%
Return on Assets-20.83%
Shares Outstanding33.99M
Shares Float5.81M
Beta1.83
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 2 analystsTarget 14.00
  • Buy
    2

Ownership Breakdown

Institutions
11.47%
Insiders
72.57%
Retail / Other
15.96%

Top Institutional Holders

  • Armistice Capital, LLC
    3.28M9.65%
  • Millennium Management LLC
    341.81K1.01%
  • Vanguard Capital Management, LLC
    132.15K0.39%
  • Geode Capital Management, LLC
    79.43K0.23%
  • Vanguard Fiduciary Trust Co
    62.74K0.18%
  • Northern Trust Corp
    23.78K0.07%
  • The Goldman Sachs Group Inc
    14.60K0.04%
  • Marshall Wace Asset Management Ltd
    11.76K0.03%
  • Citadel Advisors Llc
    11.74K0.03%
  • Tower Research Capital LLC
    8.07K0.02%
  • UBS Group AG
    7.08K0.02%
  • Mercer Global Advisors Inc.
    5500.00%
  • Activest Wealth Management
    1200.00%
  • BlackRock Inc
    300.00%

Top Fund Holders

  • Fidelity Extended Market Index
    56.97K0.17%
  • iShares Micro-Cap ETF
    26.45K0.08%
  • Fidelity Series Total Market Index
    13.06K0.04%
  • Fidelity Nasdaq Composite Index
    3.77K0.01%
  • Fidelity Total Market Index
    2.29K0.01%
  • 1290 VT Micro Cap K
    1.89K0.01%

Stock Splits

  • Oct 9, 20241:25